|
09 Nov 2023 |
TFF Pharmaceuticals Announces Publication of Data Demonstrating Feasibility of Intranasal Delivery of Monoclonal Antibodies with Thin Film Freezing
|
|
09 Nov 2023 |
Allgenesis Announces Encouraging Preliminary Safety and Efficacy Data from the AG-73305 Phase 2a Trial for the Treatment of Diabetic Macular Edema at American Academy of Ophthalmology
|
|
08 Nov 2023 |
Araris Biotech AG Announces Research Collaboration with Taiho Pharmaceutical to Develop Next-Generation ADCs Using Araris’ Proprietary Linker-Conjugation Technology
|
|
08 Nov 2023 |
Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line Treatment in All-comer Patients with Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GE
|
|
08 Nov 2023 |
Phase 2 Nipocalimab Data Establish Proof of Mechanism in Adults Living with Moderate to Severe Rheumatoid Arthritis, Supporting its Progression into a Combination Study
|
|
07 Nov 2023 |
Biotheus Enters Into Strategic Partnership with BioNTech to Develop and Commercialize Bispecific Antibody Candidate Targeting PD-L1 and VEGF in Multiple Solid Tumor Indications
|
|
07 Nov 2023 |
BioRay Announces First-Patient-In for Phase I Clinical Study of BRY812, a Novel LIV-1 Targeting Antibody Drug Conjugate
|
|
07 Nov 2023 |
Orum Therapeutics Announces Acquisition of ORM-6151 Program by Bristol Myers Squibb
|
|
06 Nov 2023 |
Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab
|
|
06 Nov 2023 |
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
|
|
06 Nov 2023 |
Innovent Presents Clinical Data of Two Ophthalmic Bispecific Antibodies IBI302 (anti-VEGF/complement) and IBI324 (anti-VEGF-A/Ang-2) at American Academy of Ophthalmology (AAO) Annual Meeting 2023
|
|
05 Nov 2023 |
Sanyou Bio Congratulates KangaBio on their IND Approval for Next-Generation IL-12 Prodrug Cancer Immunotherapy
|
|
04 Nov 2023 |
Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting
|
|
04 Nov 2023 |
Scholar Rock Presents New Data from Phase 1 DRAGON Trial Showing Promising Anti-Tumor Activity in Anti-PD-1 Resistant Metastatic ccRCC Patients and Supporting SRK-181 Continued Tolerability
|
|
03 Nov 2023 |
Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023
|
|
03 Nov 2023 |
Cidara Therapeutics Presents Preclinical Data on Novel Drug-Fc Conjugate CBO421 at SITC’s 38ᵗʰ Annual Meeting
|
|
03 Nov 2023 |
Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023
|
|
03 Nov 2023 |
Integral Molecular Unveils Trispecific Molecules Targeting GPRC5D, BCMA, and CD3 for Multiple Myeloma
|
|
03 Nov 2023 |
ProfoundBio Presents Promising Data on ADC Programs, Including Early Clinical Results of Rinatabart Sesutecan in Ovarian and Endometrial Cancers, at SITC 2023
|
|
03 Nov 2023 |
OncoNano Medicine Announces Positive Preclinical Data for ON-BOARD™ IL-12 Program at SITC 2023 Annual Meeting
|
|
03 Nov 2023 |
Tallac Presents First Clinical Data for TAC-001 at SITC 2023
|
|
03 Nov 2023 |
Xencor Presents Preclinical Data from Multiple XmAb® Research Programs at the SITC Annual Meeting
|
|
03 Nov 2023 |
AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023
|
|
03 Nov 2023 |
Ichnos Sciences announces initiation of first-in-human clinical trial for ISB 2001
|
|
03 Nov 2023 |
Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma
|
